Kenar D Jhaveri
Overview
Explore the profile of Kenar D Jhaveri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
240
Citations
3557
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Attieh R, Wehbe K, Khaled W, Jhaveri D, Me H, Bhutta S, et al.
Clin Kidney J
. 2025 Mar;
18(3):sfaf019.
PMID: 40046819
No abstract available.
2.
Merzkani M, Attieh R, Jhaveri K, Murakami N
Am J Nephrol
. 2025 Feb;
:1-23.
PMID: 39978323
Background Kidney transplant is a treatment of choice for end-stage kidney disease, with longer survival and better quality of life post-transplant. However, long-term immunosuppression comes with an increased risk of...
3.
Toriu N, Yamamoto S, Matsubara T, Kataoka Y, Sakai K, Funakoshi T, et al.
Clin Kidney J
. 2025 Feb;
18(2):sfae430.
PMID: 39959911
Background: Cancer is a leading cause of death among patients on hemodialysis; however, the data on its diagnosis, treatment and prognosis are limited. Here we analyzed the surgical practice patterns...
4.
Jhaveri K, Meena P, Bharati J, Bathini S
Indian J Nephrol
. 2025 Jan;
35(1):8-20.
PMID: 39872253
Multiple myeloma (MM) represents a difficult-to-treat plasma cell malignancy and the second most common hematologic malignancy in adults, significantly impacting kidney function. The spectrum of kidney involvement in MM is...
5.
Ghani M, Alisan B, Barmas-Alamdari D, Attieh R, Jhaveri K
Am J Ther
. 2025 Jan;
31(6):e652-e658.
PMID: 39792491
Background: C3 glomerulopathy (C3G) is a rare disease affecting the complement alternative pathway, categorized into dense deposit disease and C3 glomerulonephritis. Dense deposit disease predominantly affects younger individuals, while C3...
6.
Izzedine H, Jhaveri K, Courbebaisse M
N Engl J Med
. 2025 Jan;
392(1):104.
PMID: 39752314
No abstract available.
7.
Kuwabara T, Miyasato Y, Kanki T, Mizumoto T, Matsubara T, Sawa N, et al.
Clin Kidney J
. 2024 Dec;
17(12):sfae327.
PMID: 39664993
Background: Kidney complications associated with anticancer drug therapy have greatly increased recently. We aimed to investigate the real-world clinical outcomes of anticancer drug therapy-associated renal complications in Japan using the...
8.
Koirala A, Sharma P, Jhaveri K, Jain K, Geetha D
Adv Kidney Dis Health
. 2024 Nov;
31(6):485-495.
PMID: 39577882
Rapidly progressive glomerulonephritis (RPGN) is a syndrome characterized by a swift decline in kidney function, often over a few months, accompanied by features of nephritic syndrome. It can result in...
9.
Attieh R, Upadrista P, Levy A, Jhaveri K
Clin Nephrol
. 2024 Nov;
103(1):12-18.
PMID: 39559834
Introduction: Fibroblast growth factor inhibitors (FGFRi) are novel cancer drugs that offer new hope for patients with advanced biliary tract cancers and metastatic urothelial tumors. Despite their effectiveness, they often...
10.
Gupta S, Glezerman I, Hirsch J, Wells S, Chen K, Seitter R, et al.
Nephrol Dial Transplant
. 2024 Oct;
40(2):405-408.
PMID: 39415423
No abstract available.